These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23400746)

  • 1. Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.
    Kim JW; Yi S; Kim TE; Lim KS; Yoon SH; Cho JY; Lee MG; Song IS; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2013 Jan; 53(1):75-81. PubMed ID: 23400746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
    Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
    Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.
    Choi MK; Jin QR; Choi YL; Ahn SH; Bae MA; Song IS
    Biopharm Drug Dispos; 2011 Apr; 32(3):175-84. PubMed ID: 21456052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.
    Gu N; Cho JY; Shin KH; Jang IJ; Rhee MY
    Drug Des Devel Ther; 2016; 10():1525-31. PubMed ID: 27143858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.
    Lee J; Rhee SJ; Lee S; Yu KS
    Drug Des Devel Ther; 2018; 12():787-794. PubMed ID: 29670335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatic dysfunction on the pharmacokinetics and safety of fimasartan.
    Kim CO; Lee HW; Oh ES; Seong SJ; Kim DY; Lee J; Ahn SH; Yoon YR; Cho CM; Park MS
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):524-9. PubMed ID: 24084213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.
    Kang WY; Lee HW; Gwon MR; Cho S; Shim WS; Lee KT; Yang DH; Seong SJ; Yoon YR
    Drug Des Devel Ther; 2020; 14():2101-2111. PubMed ID: 32546973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
    Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
    Kang WY; Kim EH; Seong SJ; Gwon MR; Yang DH; Kim HJ; Lim MS; Lee HW; Yoon YR
    Int J Clin Pharmacol Ther; 2016 Dec; 54(12):992-1003. PubMed ID: 27668695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.
    Ghim JL; Paik SH; Hasanuzzaman M; Chi YH; Choi HK; Kim DH; Shin JG
    J Clin Pharmacol; 2016 May; 56(5):576-80. PubMed ID: 26272450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects.
    Kang WY; Seong SJ; Ohk B; Gwon MR; Kim BK; Cho S; Shim WS; Lee KT; Kim EH; Yang DH; Lee HW; Yoon YR
    Drug Des Devel Ther; 2018; 12():3607-3615. PubMed ID: 30464392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets.
    Hwang JG; Yu KS; Lee S
    Drug Des Devel Ther; 2020; 14():1953-1961. PubMed ID: 32546962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
    Choi Y; Lee S; Jang IJ; Yu KS
    Drug Des Devel Ther; 2018; 12():2301-2309. PubMed ID: 30087555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
    Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
    Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):585-611. PubMed ID: 19936896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fimasartan, a novel angiotensin II receptor antagonist.
    Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
    Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.